Get notified when MDT files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (new) — The notes section emitted a red flag for 'material weakness' but the quote is from litigation disclosure and does not indicate an actual control weakness; this flag appears to be a false positive and should be disregarded.
NYSE: MDT Medtronic plc 10-Q

Medtronic Q1 FY27: sales +13.7% to $9.76B, net income +41.3% to $1.47B; MiniMed IPO, two acquisitions, and hernia mesh verdict

Filed September 3, 2026 · Period ending July 31, 2026 · Compared to 10-Q Aug 26, 2025 · ~1 min read

Key Changes

  • high

    Total net sales rose 13.7% to $9.76B (~$570M); net income jumped 41.3% to $1.47B, diluted EPS $1.14 (+40.7%).

    MD&A: Net sales verify on EDGAR →
  • high

    MiniMed completed its IPO in March 2026; Medtronic retains control and plans full separation of the Diabetes business within fiscal 2027.

    Notes: MiniMed separation verify on EDGAR →
  • high

    Acquired Scientia Vascular ($681M) and SPR Therapeutics ($654M), expanding the Neuroscience portfolio.

    Notes: Acquisitions verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.

Partner

Trade MDT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 4, 2026 · How we verify